Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Migraines Clear all
Completed Phase 2Phase 3 Interventional Results available

Low-dose Propofol for Pediatric Migraine

NCT01604785
View directory record Official record
Conditions
Migraine Headache
Interventions
Propofol, Standard Treatment
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
7 Years to 18 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 17, 2026, 2:24 AM EDT
Terminated Not applicable Interventional

Feasibility of Using a Mobile Device Controlled Micro-pressure Pulse Insufflator for Acute Migraine Relief

NCT03263897
View directory record Official record
Conditions
Migraine
Interventions
insufflation, placebo insufflation
Device
Lead sponsor
Caps Research Network
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Prescott, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

NCT03557333
View directory record Official record
Conditions
Migraine Headache
Interventions
INP104
Combination Product
Lead sponsor
Impel Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 17, 2026, 2:24 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)

NCT02964741
View directory record Official record
Conditions
Migraine
Interventions
Active Comparator, Sham Comparator
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Mind and Body Approaches to Pain Reduction in Youth With Migraine

NCT03472092
View directory record Official record
Conditions
Headache, Migraine, Migraine, Migraine Disorders, Headache
Interventions
Cognitive Behavioral Therapy (CBT), Placebo, Amitriptyline, Biofeedback-Assisted Relaxation Training (BART), Cognitive Reappraisal Training (CR)
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 17, 2026, 2:24 AM EDT
Completed No phase listed Observational Results available

Research Study to Determine Sensitivity to Gentle Touch and Pressure During an Active Migraine Attack.

NCT00329771
View directory record Official record
Conditions
Migraine
Interventions
No intervention: We are testing for the presence of allodynia
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

NCT00387881
View directory record Official record
Conditions
Migraine, Without Aura
Interventions
sumatriptan succinate / naproxen sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
70
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 17, 2026, 2:24 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444
View directory record Official record
Conditions
Chronic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

NCT02559895
View directory record Official record
Conditions
Migraine Disorders
Interventions
ALD403, Placebo
Drug
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
898 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 17, 2026, 2:24 AM EDT
Completed No phase listed Observational

Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention

NCT03662295
View directory record Official record
Conditions
Migraine Disorders, Aphasia
Interventions
Language treatment
Behavioral
Lead sponsor
Quality Living, Inc.
Other
Eligibility
19 Years to 65 Years
Enrollment
1 participant
Timeline
2018 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

NCT03631550
View directory record Official record
Conditions
Acute Migraine
Interventions
Relivion active, Relivion Sham
Device
Lead sponsor
Neurolief Ltd.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Tempe, Arizona • Hartford, Connecticut • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 17, 2026, 2:24 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Peri-neural Electrical Dry Needling Migraine Treatment Study

NCT04252391
View directory record Official record
Conditions
Migraine Headache
Interventions
Perineural electrical dry needling, Standard Care
Procedure
Lead sponsor
Wheaton Franciscan Healthcare
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 17, 2026, 2:24 AM EDT
Recruiting Phase 4 Interventional

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

NCT06401642
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Results available

Diphenhydramine for Acute Migraine

NCT01825941
View directory record Official record
Conditions
Migraine
Interventions
metoclopramide, diphenhydramine, placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

NCT03040479
View directory record Official record
Conditions
Migraine
Interventions
lasmiditan 200 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Results available

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

NCT04271202
View directory record Official record
Conditions
Chronic Migraine
Interventions
Emgality 120 MG in 1 ML Prefilled Syringe
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 17, 2026, 2:24 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

NCT01981499
View directory record Official record
Conditions
Migraine
Interventions
PF-05180999, Placebo, 120 mg MR PF-05180999, 360 mg MR PF-05180999, 10 mg cetirizine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

NCT02985398
View directory record Official record
Conditions
Migraine Disorder
Interventions
ALD403 (Eptinezumab)
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
20
States / cities
San Diego, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 17, 2026, 2:24 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches

NCT00391755
View directory record Official record
Conditions
Migraine Headache
Interventions
ramelteon
Drug
Lead sponsor
Charlottesville Neuroscience
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

NCT03832998
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 17, 2026, 2:24 AM EDT
Not listed Phase 4 Interventional

American Migraine Prevention Study

NCT00363506
View directory record Official record
Conditions
Migraine Disorders
Interventions
Serotona Plus and dietary behavior management
Behavioral
Lead sponsor
Dynamic Health Resources
Industry
Eligibility
18 Years to 72 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chesapeake, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2008 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Assessment of ALD403 in Chronic Migraine

NCT02275117
View directory record Official record
Conditions
Migraine Disorders
Interventions
ALD403, Placebo
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
82
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Intramuscular Ropivacaine Injections for Treatment of Pediatric Headache

NCT00680823
View directory record Official record
Conditions
Headache, Migraine
Interventions
Ropivacaine, Normal saline
Drug
Lead sponsor
Robert Hickey
Other
Eligibility
7 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 17, 2026, 2:24 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine

NCT03337620
View directory record Official record
Conditions
Headache, Migraine
Interventions
Tx360
Device
Lead sponsor
Tian Medical Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
New Haven, Connecticut • Stamford, Connecticut • Fort Gordon, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 17, 2026, 2:24 AM EDT